The recommended dose for Skyrizi is 150 mg – administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and 4. It can be administered in-office or by ...
(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...